Fig. 6
From: Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER
A Gender subgroup analysis of Faricimab-associated AEs in the FAERS database, comparing AE occurrences between male and female patients, with the top 30 most frequently reported AEs displayed. B Age subgroup analysis of Faricimab-associated AEs in the FAERS database, comparing younger (<65 years) and older (≥65 years) patients, with the top 30 most frequently reported AEs displayed. The forest plot presents the reporting odds ratio (ROR) with 95% confidence intervals (CI), highlighting subgroup differences